Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by StockNews.com to Sell Rating

StockNews.com upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP) to a sell rating in a report published on Monday morning.

A number of other analysts have also recently issued reports on CRBP. Piper Sandler assumed coverage on Corbus Pharmaceuticals in a research report on Monday, December 2nd. They issued an “overweight” rating and a $35.00 price objective for the company. B. Riley reduced their price objective on shares of Corbus Pharmaceuticals from $85.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, September 20th. Mizuho reissued an “outperform” rating and issued a $74.00 price objective on shares of Corbus Pharmaceuticals in a research report on Friday, September 20th. Royal Bank of Canada reiterated an “outperform” rating and issued a $82.00 price target on shares of Corbus Pharmaceuticals in a research note on Friday, September 20th. Finally, Wedbush reissued an “outperform” rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Corbus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $62.00.

Corbus Pharmaceuticals Stock Performance

Shares of CRBP stock opened at $11.30 on Monday. Corbus Pharmaceuticals has a 52-week low of $5.67 and a 52-week high of $61.90. The stock has a market cap of $137.62 million, a price-to-earnings ratio of -2.41 and a beta of 2.63. The firm’s 50-day moving average is $15.26 and its 200-day moving average is $32.72.

Institutional Trading of Corbus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of CRBP. Vestcor Inc acquired a new stake in shares of Corbus Pharmaceuticals in the third quarter valued at approximately $64,000. JPMorgan Chase & Co. increased its stake in Corbus Pharmaceuticals by 27.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 1,172 shares during the period. MetLife Investment Management LLC acquired a new position in Corbus Pharmaceuticals in the 3rd quarter valued at $123,000. SG Americas Securities LLC acquired a new position in Corbus Pharmaceuticals in the 3rd quarter valued at $151,000. Finally, FMR LLC lifted its position in shares of Corbus Pharmaceuticals by 33.0% during the 3rd quarter. FMR LLC now owns 10,028 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 2,486 shares during the period. Institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.